|Bid||53.40 x 800|
|Ask||69.73 x 1100|
|Day's Range||53.17 - 55.59|
|52 Week Range||31.75 - 65.09|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||32.37|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.00|
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The one and a half month time period since the end of the […]
PRA Health Sciences (PRAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PRA Health stock broke out Thursday amid a broad boost for medical research stocks. Medical research stocks are benefiting from inflows into biotechs.
Many growth stocks have gotten hurt as the market turned south during the past week. But Medpace Holdings is showing unusual strength.
Anyone researching Medpace Holdings Inc (NASDAQ:MEDP) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...
Medpace Holdings, Inc. today announced that it will present at the following investor conference in November:
NEW YORK, Nov. 01, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Medpace (MEDP) delivered earnings and revenue surprises of 6.35% and 2.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cincinnati-based company said it had profit of 52 cents. Earnings, adjusted for one-time gains and costs, came to 67 cents per share. The results topped Wall Street expectations. ...
CINCINNATI-- -- Revenue was $179.3 million in the third quarter of 2018. Net new business awards were $227.6 million in the third quarter. GAAP net income was $19.3 million, or $0.52 per diluted share, and net income margin was 10.8% in the third quarter of 2018. Adjusted EBITDA was $36.4 million for the third quarter of 2018, resulting in an Adjusted EBITDA margin of 20.3%. Adjusted Net Income was ...
Medpace Holdings' (MEDP) revenue growth in Q3 to be driven by strength in oncology, cardiometabolic, antiviral and anti-infectious diseases solutions.
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In this article I am going to calculate the intrinsic value of Medpace Holdings Inc (NASDAQ:MEDP) by taking the foreast future cash flows of the company and discounting them back Read More...
Greater Cincinnati stocks didn’t escape the damage as the broad stock market got slammed Wednesday with the Dow Jones Industrial Average plummeting more than 800 points to suffer its worst one-day drop since February.
NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Medpace Holdings, Inc. today announced that it will report its third quarter 2018 financial results after the market close on Monday, October 29, 2018. The Company will host a conference call the following morning, Tuesday, October 30, 2018, at 9:00 a.m.
President & CEO of Medpace Holdings Inc (NASDAQ:MEDP) August J. Troendle sold 132,304 shares of MEDP on 09/27/2018 at an average price of $58.58 a share.